Clinical Trial Update: Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial in non-small cell lung cancer compared PR-104 alone to PR-104 with docetaxel and was terminated with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PR-104

Snippet

Sponsor: Proacta, Incorporated | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-01-10